Simponi aria and Nausea and vomiting - a phase IV clinical study of FDA data

Summary:

Nausea and vomiting is reported as a side effect among people who take Simponi aria (golimumab), especially for people who are female, 60+ old, have been taking the drug for 1 - 6 months also take Arava, and have Dizziness.

The phase IV clinical study analyzes which people have Nausea and vomiting when taking Simponi aria. It is created by eHealthMe based on reports of 3,676 people who have side effects when taking Simponi aria from the FDA, and is updated regularly.

What is Simponi aria?

Simponi aria has active ingredients of golimumab. eHealthMe is studying from 3,704 Simponi aria users. Check the latest studies of Simponi aria.

What is Nausea and vomiting?

Nausea and vomiting is found to be associated with 3,712 drugs and 5,746 conditions by eHealthMe. Check the latest studies of Nausea and vomiting.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 30, 2026

3,676 people reported to have side effects when taking Simponi aria.
Among them, 62 people (1.69%) have Nausea and vomiting.

Could Simponi aria cause Nausea and vomiting?

Among these 62 people:

How long have people been on Simponi aria when they have Nausea and vomiting? *

What is the gender of people who have Nausea and vomiting when taking Simponi aria? *

female: 94.92 %
male: 5.08 %

What is the age of people who have Nausea and vomiting when taking Simponi aria? *

What are other drugs people take besides Simponi aria? *

What are other side effects people have besides Nausea and vomiting? *

Nausea (feeling of having an urge to vomit): 47 people, 75.81%
Rashes (redness): 38 people, 61.29%
Diarrhea: 38 people, 61.29%
Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 37 people, 59.68%
Dyspnea (difficult or laboured breathing): 36 people, 58.06%
Fatigue (feeling of tiredness): 36 people, 58.06%
Chills (felling of cold): 35 people, 56.45%
Back Pain: 35 people, 56.45%
Headache (pain in head): 34 people, 54.84%
Muscle Aches (muscle pain): 34 people, 54.84%

What are the existing conditions these people have? *

Dizziness: 33 people, 53.23%
Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 15 people, 24.19%
Pain: 12 people, 19.35%
High Blood Pressure: 4 people, 6.45%
Asthma: 3 people, 4.84%
Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 3 people, 4.84%
Hypersensitivity: 2 people, 3.23%
Vitamin D Decreased: 2 people, 3.23%
Psoriasis (immune-mediated disease that affects the skin): 2 people, 3.23%
Panic Disorder: 1 person, 1.61%

* Approximation only. Some reports may have incomplete information.

Do you take Simponi aria and have Nausea and vomiting?

- Check whether Nausea and vomiting is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Simponi aria:

Simponi aria (3,704 reports)

Browse all side effects of Simponi aria:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Nausea and vomiting:

Nausea and vomiting (3,712 drugs)

Browse all the conditions that are associated with Nausea and vomiting:

Nausea and vomiting (5,746 conditions)

Related publications that referenced our studies

Azuma N, Matsui K, Hashimoto N, Yoshikawa T, Sano H, "Successful Switch to Golimumab for Eosinophilia and Skin Symptoms Related to Multiple Biologics in a Patient with Rheumatoid Arthritis", Internal Medicine, 2017 Jun .
Azuma N, Matsui K, Hashimoto N, Yoshikawa T, Sano H, "Successful Switch to Golimumab for Eosinophilia and Skin Symptoms Related to Multiple Biologics in a Patient with Rheumatoid Arthritis", Internal Medicine, 2017 Jun .

How the study uses the data?

The study uses data from the FDA. It is based on golimumab (the active ingredients of Simponi aria) and Simponi aria (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.